Blocking alpha4-integrins - A small molecule approach to treatment of multiple sclerosis.
Inhibition of leukocyte trafficking using antibody blockade of the alpha4 (alpha4)-integrins has now been validated as a therapeutic approach for the treatment of multiple sclerosis (MS). This positive validation has led to the discovery of small molecule alpha4 antagonists that are progressing through clinical trials. The challenges in development of these antagonists will be discussed along with a clinical update on the most advanced candidates.
Davenport
Richard J
RJ
UCB, Granta Park, Great Abington, Cambridge, CB21 6GS, UK. rdavenport@takedacam.com
Munday
James R
JR
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D039441:Integrin alpha4 / Q000276:immunology* / Q000378:metabolism*; D008954:Models, Biological; D008958:Models, Molecular; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000906:Antibodies; D007166:Immunosuppressive Agents; D039441:Integrin alpha4